|Articles|February 12, 2008
CEO of Genelabs Resigns
Author(s)BioPharm International Editors
James A.D. Smith, president, chief executive officer, and director of Genelabs Technologies, Inc. (Redwood City, CA) has resigned.
Advertisement
James A.D. Smith, president, chief executive officer, and director of Genelabs Technologies, Inc. (Redwood City, CA) has resigned. Until a successor is appointed, Irene A. Chow, executive chair of Genelabs’ board of directors, and Frederick W. Driscoll, CFO, will assume leadership responsibilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
2
Charles River Incubator Cohort to Accelerate CGT Development
3
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
4
FAQ: Shifts in FDA Regulations and Strategies in 2025
5
